Polaris Group announced that the first patient was dosed with ADI-PEG 20 in the Phase II a clinical trial for NASH at Chang Gung Memorial Hospital, Linkou, Taiwan. This Phase II clinical trial is a multicenter, randomized, double-blind, placebo-controlled trial that will include 60 patients from at least 5 clinical sites across Taiwan that aims to evaluate the safety, tolerability, and preliminary efficacy of the company's investigational drug ADI-PEG 20 in patients with NASH. Participants will receive ADI-PEG 20 or a placebo to assess the drug's impact on liver fat content, liver histology, and various other endpoints.

The study is part of Polaris Group's broader commitment to pioneering advancements in the treatment of metabolic diseases. The company's investigational drug, ADI-PEG 20, holds promise as a potential therapy for NASH. By targeting key pathways involved in NASH pathogenesis, this innovative drug has the potential to address the root causes of the disease.

Polaris Group is proud to collaborate with leading researchers, healthcare professionals, and patients on this important journey to develop a treatment for NASH. The company is dedicated to conducting rigorous research and adhering to the highest standards of safety and ethics throughout this trial. ADI-PEG 20, developed by Polaris Group, operates through a unique mechanism of action.

It utilizes metabolic therapy to degrade arginine in the blood and can be combined with other cancer treatment modalities to produce synergistic effects.